Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

What We're Reading

Literature Highlights: Impactful Papers Published Elsewhere

Article Recommendations from Our Deputy and Senior Editors

DOI:  Published May 2018
  • Article
  • Info & Metrics
  • PDF
Loading

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes


Embedded Image

Engineering safer immunolocks and keys (by Wapcaplet via Wikimedia Commons)

IL2 therapy is used with caution due to adverse events at IL2 concentrations that are clinically useful. A modified IL2 receptor, which only binds to a modified form of IL2, was inserted into T cells destined for adoptive antitumor therapy. The modified IL2 was designed to only bind the modified receptor, and, as administration of this modified IL2 activates only the transferred T cells, the IL2 provides not only therapeutic benefit but also is not associated with identifiable toxicity.

Sockolosky JT, …, Garcia KC. Science 2018 Mar 2;359:1037–42.

Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumor cells


Embedded Image

Fibroblast engulfing debris (From Lakins et al.)

Tumor fibroblasts were found to engulf and process tumor cell debris, then cross-present it to T cells. However, instead of activating T cells, this presentation is suppressive and reduces T-cell viability. The T-cell death results from increased expression of FasL and PD-L2 on the fibroblasts that, in turn, activates Fas and PD-1 pathways in the T cells. Blockade of these interactions restored antigen-specific T-cell killing of tumor cells.

Lakins MA, …, Shields JD. Nat Commun 2018 Mar 5. DOI: 10.1038/s41467-018-03347-0.

Macrophage manipulation to improve antitumor responses


Embedded Image

Tumor-associated macrophage clusters (from Perry et al., Fig. 2)

Immunotherapeutics are hampered by suppressive elements in the tumor microenvironment, including M2 (suppressive) macrophages. Perry et al., using an authochthonous mouse model (mutant Braf/Pten) of melanoma, and Hoves et al., primarily with the MC38 model, show that activating CD40 while inhibiting CSF-1R signaling changes transcriptional modules, reduces M2s, increases inflammatory macrophages, and improves tumor control. The effects are strong, but not permanent, and both CD8+ T cells and macrophages are necessary for tumor eradication.

Perry CJ, …, Kaech SM. J Exp Med 2018 Feb 7;215:877–93.

Hoves S, …, Ries CH. J Exp Med 2018 Feb 7;215:859–76.

Fc effector function contributes to the activity of human anti–CTLA-4 antibodies


Embedded Image

Fc affinity affects checkpoint blockade effectiveness (from Arce Vargas et al.)

Optimization of the interaction between human FcγRs and anti– CTLA-4 in humanized mice expressing human FcγRs efficiently depletes Tregs and controls tumor growth. However, removal of Tregs is only important in tumors that are highly inflamed and infiltrated by CD8+ T cells. Patients carrying FcγR polymorphisms with higher binding affinities for IgGs, and that have higher neoantigen burdens, show greater responses to CTLA-4 blockade.

Arce Vargas F, …, Quezada SA. Cancer Cell 2018 Mar 22. DOI: 10.1016/j.ccell.2018.02.010.

4-1BB costimulation regulates antitumor T-cell metabolic function and enhances immunotherapies


Embedded Image

4-1BB–activated mitochondria (from Teijeira et al., Fig. 6)

Removing checks on T-cell activation is often insufficient for reactivating CD8+ T cells. Inducing 4-1BB signaling while blocking PD-1 (Menk et al.) or during adoptive T-cell therapy (Teijeira et al.) induces robust antitumor immunity in mouse models of melanoma or colon cancer. 4-1BB appears to regulate mitochondrial mass and function, reprogramming the metabolic state of antitumor T cells to counter exhaustion.

Menk AV, …, Delgoffe GM. J Exp Med 2018 Mar 6. DOI: 10.1084/jem.20171068.

Teijeira A, …, Melero I. Cancer Immunol Res 2018 Apr. DOI: 10.1158/2326-6066.CIR-17-0767.

Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases


Embedded Image

Core of hydrogel (by Edgar181 via Wikimedia Commons)

Surgery removes primary tumors, but the wound healing process produces an immunosuppressive environment that may be conducive to regrowth of residual tumor cells and distal metastasis. Placing a hydrogel laced with agonists for innate immune responses into post-surgical wounds from which tumors had been extracted resulted in activation of innate and specific antitumor responses and a decrease in metastasis.

Park CG, …, Goldberg MS. Sci Transl Med 2018 Mar 21;10:eaar1916.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Immunology Research: 6 (5)
May 2018
Volume 6, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Literature Highlights: Impactful Papers Published Elsewhere
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Literature Highlights: Impactful Papers Published Elsewhere
Cancer Immunol Res May 1 2018 (6) (5) 501;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Literature Highlights: Impactful Papers Published Elsewhere
Cancer Immunol Res May 1 2018 (6) (5) 501;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
    • Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumor cells
    • Macrophage manipulation to improve antitumor responses
    • Fc effector function contributes to the activity of human anti–CTLA-4 antibodies
    • 4-1BB costimulation regulates antitumor T-cell metabolic function and enhances immunotherapies
    • Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Sampling of Highlights from the Literature
  • A Sampling of Highlights from the Literature
  • A Sampling of Highlights from the Literature
Show more What We're Reading
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement